George Mulligan

Summary

Affiliation: Millennium Pharmaceuticals
Country: USA

Publications

  1. ncbi request reprint Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
    George Mulligan
    Clinical Research Translational Medicine, Millennium Pharmaceuticals Inc, 40 Landsdowne Street, Cambridge, MA 02139, USA
    Blood 109:3177-88. 2007
  2. pmc Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone
    David I Lichter
    Millennium Pharmaceuticals, 35 Landsdowne St, Cambridge, MA 02139, USA
    Blood 120:4513-6. 2012
  3. doi request reprint An historic perspective of proteasome inhibition
    Dixie Lee Esseltine
    Oncology Clinical Research, Millennium Pharmaceuticals, Inc, Cambridge, MA 02139, USA
    Semin Hematol 49:196-206. 2012
  4. ncbi request reprint Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events
    Wee J Chng
    Blood 109:3610-1. 2007
  5. ncbi request reprint Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling
    Wee J Chng
    Department of Hematology Oncology, Mayo Clinic, Scottsdale, Arizona, USA
    Cancer Res 67:2982-9. 2007
  6. pmc Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma
    Jonathan J Keats
    Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Cancer Cell 12:131-44. 2007
  7. ncbi request reprint The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition
    Wee J Chng
    Department of Hematology Oncology, Mayo Clinic, Scottsdale, AZ, USA
    Blood 111:1603-9. 2008
  8. pmc High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone
    Fenghuang Zhan
    Blood 111:968-9. 2008

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
    George Mulligan
    Clinical Research Translational Medicine, Millennium Pharmaceuticals Inc, 40 Landsdowne Street, Cambridge, MA 02139, USA
    Blood 109:3177-88. 2007
    ..Informative gene expression data and genomic classifiers that predict clinical outcome can be derived from prospective clinical trials of new anticancer agents...
  2. pmc Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone
    David I Lichter
    Millennium Pharmaceuticals, 35 Landsdowne St, Cambridge, MA 02139, USA
    Blood 120:4513-6. 2012
    ....
  3. doi request reprint An historic perspective of proteasome inhibition
    Dixie Lee Esseltine
    Oncology Clinical Research, Millennium Pharmaceuticals, Inc, Cambridge, MA 02139, USA
    Semin Hematol 49:196-206. 2012
    ..We describe the development of bortezomib and the elucidation of the effects of its novel mechanism of action, and place the cutting-edge work described elsewhere in this issue in the context of these historic developments...
  4. ncbi request reprint Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events
    Wee J Chng
    Blood 109:3610-1. 2007
  5. ncbi request reprint Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling
    Wee J Chng
    Department of Hematology Oncology, Mayo Clinic, Scottsdale, Arizona, USA
    Cancer Res 67:2982-9. 2007
    ..Furthermore, the signatures that defined these clusters may provide a basis for tailoring treatment to individual patients...
  6. pmc Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma
    Jonathan J Keats
    Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Cancer Cell 12:131-44. 2007
    ..These results highlight the critical importance of the NF-kappaB pathway in the pathogenesis of multiple myeloma...
  7. ncbi request reprint The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition
    Wee J Chng
    Department of Hematology Oncology, Mayo Clinic, Scottsdale, AZ, USA
    Blood 111:1603-9. 2008
    ..Human myeloma cell lines with higher CI are more responsive to treatment with a novel aurora kinase inhibitor. Aurora kinase may represent novel therapeutic targets in these patients with very poor prognosis...
  8. pmc High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone
    Fenghuang Zhan
    Blood 111:968-9. 2008